Plans to reduce its workforce by 55% to extend its cash runway as the company explores strategic alternatives with the goal of maximizing stockholder value.
Voyager gains worldwide rights to VY-HTT01 Huntington’s disease program and ex-U.S. rights to VY-FXN01 Friedreich’s ataxia program for $10 million upfront
Operational changes include relocating its U.S. workforce from six current locations into three existing facilities in Weston and Cambridge, MA, and Research Triangle Park, NC.